Overview

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Status:
Completed

Trial end date:
2020-03-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, tolerability and antitumor activity of IMAB362 in Japanese subjects with locally advanced or metastatic Gastric or GEJ adenocarcinoma whose tumors have Claudin (CLDN) 18.2 Expression. This study will also assess pharmacokinetics and immunogenicity of IMAB362.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Antibodies, Monoclonal